Grazia Arpino
About
Grazia Arpino is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Grazia Arpino has authored 157 papers receiving a total of 6.7k indexed citations (citations by other indexed papers that have themselves been cited), including 111 papers in Oncology, 74 papers in Cancer Research and 57 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Grazia Arpino's work include HER2/EGFR in Cancer Research (62 papers), Breast Cancer Treatment Studies (60 papers) and Advanced Breast Cancer Therapies (49 papers). Grazia Arpino is often cited by papers focused on HER2/EGFR in Cancer Research (62 papers), Breast Cancer Treatment Studies (60 papers) and Advanced Breast Cancer Therapies (49 papers). Grazia Arpino collaborates with scholars based in Italy, United States and France. Grazia Arpino's co-authors include Richard Elledge, C. Kent Osborne, Sabino De Placido, Rachel Schiff, Gary M. Clark, V J Bardou, Mario Giuliano, Adrian V. Lee, Michelino De Laurentiis and Valérie‐Jeanne Bardou and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Internal Medicine and Journal of the American College of Cardiology.
In The Last Decade
Grazia Arpino
144 papers receiving 6.6k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Grazia Arpino Italy | 37 | 4.2k | 2.8k | 1.7k | 1.6k | 1.6k | 157 | 6.7k | ||
| Rinat Yerushalmi Israel | 27 | 4.4k 1.1× | 2.3k 0.8× | 2.2k 1.3× | 1.8k 1.1× | 1.2k 0.7× | 119 | 6.7k | ||
| Jacques Bonneterre France | 44 | 5.1k 1.2× | 2.8k 1.0× | 1.9k 1.1× | 1.7k 1.0× | 1.5k 0.9× | 257 | 8.0k | ||
| Robert Mennel United States | 22 | 4.2k 1.0× | 3.3k 1.2× | 1.6k 0.9× | 1.2k 0.8× | 952 0.6× | 47 | 6.7k | ||
| Nicholas J. Robert United States | 44 | 6.7k 1.6× | 4.1k 1.5× | 2.0k 1.2× | 2.0k 1.2× | 2.2k 1.4× | 181 | 10.0k | ||
| Henri Roché France | 44 | 6.4k 1.5× | 3.3k 1.2× | 2.1k 1.2× | 1.8k 1.1× | 1.3k 0.8× | 213 | 9.0k | ||
| Lynn G. Dressler United States | 27 | 5.1k 1.2× | 4.8k 1.7× | 2.7k 1.5× | 1.2k 0.8× | 1.3k 0.8× | 51 | 8.6k | ||
| Binghe Xu China | 41 | 6.1k 1.5× | 3.0k 1.1× | 3.2k 1.8× | 2.8k 1.7× | 1.2k 0.8× | 387 | 9.1k | ||
| Rita Nanda United States | 34 | 4.3k 1.0× | 2.5k 0.9× | 1.5k 0.9× | 1.4k 0.9× | 765 0.5× | 205 | 6.3k | ||
| Pär‐Ola Bendahl Sweden | 44 | 3.3k 0.8× | 3.0k 1.1× | 2.7k 1.6× | 1.4k 0.8× | 928 0.6× | 181 | 6.7k | ||
| Antonio Llombart‐Cussac Spain | 43 | 6.8k 1.6× | 3.5k 1.3× | 1.4k 0.8× | 3.9k 2.4× | 1.6k 1.0× | 317 | 9.4k |
Countries citing papers authored by Grazia Arpino
Since
Specialization
Citations
This map shows the geographic impact of Grazia Arpino's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Grazia Arpino with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Grazia Arpino more than expected).
Fields of papers citing papers by Grazia Arpino
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Grazia Arpino. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Grazia Arpino. The network helps show where Grazia Arpino may publish in the future.
Co-authorship network of co-authors of Grazia Arpino
This figure shows the co-authorship network connecting the top 25 collaborators of Grazia Arpino. A scholar is included among the top collaborators of Grazia Arpino based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Grazia Arpino. Grazia Arpino is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Arecco, Luca, Eva Blondeaux, Marco Bruzzone, et al.. (2025). Prognostic implications of risk definitions from the monarchE and NATALEE trials. JNCI Journal of the National Cancer Institute. 117(6). 1198–1208.
2.
Palleschi, Michela, Federica Martorana, Giacomo Barchiesi, et al.. (2025). Unlocking the Potential of Immune Checkpoint Inhibitors in HR+/HER2− Breast Cancer: A Systematic Review. Cancers. 17(17). 2940–2940.
3.
Lambertini, Matteo, Pietro De Placido, Sabino De Placido, et al.. (2024). Abstract PO4-03-07: The impact of chemotherapy relative dose intensity on pathological complete response in patients with triple negative breast cancer treated with neoadjuvant chemotherapy. Cancer Research. 84(9_Supplement). PO4–3.
4.
Blondeaux, Eva, Claudia Bighin, Stefania Russo, et al.. (2024). Abstract PO4-04-05: HER2 immunohistochemistry (IHC) expression in HER2-positive (HER2-pos) metastatic breast cancer (mBC): clinical and prognostic differences between IHC 2+ and IHC 3+ populations. Cancer Research. 84(9_Supplement). PO4–4.
5.
Pepe, Francesco, Jole Ventriglia, Giancarlo Troncone, et al.. (2024). Efficacy of PARP inhibitors in advanced high-grade serous ovarian cancer according to BRCA domain mutations and mutation type. Frontiers in Oncology. 14. 1412807–1412807.
6.
Molinelli, Chiara, Marco Bruzzone, Eva Blondeaux, et al.. (2024). The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study. European Journal of Cancer. 213. 115113–115113.
7.
Maïo, Massimo Di, Claudia Bighin, Francesco Schettini, et al.. (2023). Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA study. The Breast. 72. 103583–103583.
8.
Fabi, Alessandra, Matteo Allegretti, G. Ferretti, et al.. (2023). Abstract OT1-22-01: Liquid biopsy and Ado-trastuzumab emtansine (T-DM1): drug-resistance traits in the blood of HER2-positive metastatic breast cancer patients. Cancer Research. 83(5_Supplement). OT1–22.
9.
Arpino, Grazia, Giampaolo Bianchini, Giuseppe Curigliano, et al.. (2023). Breaking barriers in triple negative breast cancer (TNBC) – Unleashing the power of antibody-drug conjugates (ADCs). Cancer Treatment Reviews. 123. 102672–102672.
10.
Rizzo, Alessandro, Francesco Di Costanzo, Silvana Acquafredda, et al.. (2023). Discontinuation rate and serious adverse events of chemoimmunotherapy as neoadjuvant treatment for triple-negative breast cancer: a systematic review and meta-analysis. ESMO Open. 8(6). 102198–102198.
11.
Arx, Claudia von, Pietro De Placido, Michelino De Laurentiis, et al.. (2022). The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer. Cancer Treatment Reviews. 113. 102500–102500.
12.
Napolitano, Fabiana, Pietro De Placido, Valeria Forestieri, et al.. (2022). Insight on the Role of Leptin: A Bridge from Obesity to Breast Cancer. Biomolecules. 12(10). 1394–1394.
13.
Fabi, Alessandra, G. Ferretti, Paola Malaguti, et al.. (2020). Nanoparticle Albumin-Bound Paclitaxel/Liposomal-Encapsulated Doxorubicin in HER2-Negative Metastatic Breast Cancer Patients. Future Oncology. 16(22). 1631–1639.
14.
Rossi, Lorenzo, Chiara Biagioni, Amelia McCartney, et al.. (2019). Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial. Breast Cancer Research. 21(1). 71–71.
15.
Giuliano, Mario, Hin Ching Lo, Grazia Arpino, et al.. (2018). Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize. Cancer Research. 78(4). 845–852.
16.
Placido, Sabino De, Mario Giuliano, Francesco Schettini, et al.. (2018). Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results. The Breast. 38. 86–91.
17.
Buono, Giuseppe, Mario Giuliano, Carmine De Angelis, et al.. (2017). Pretreatment Serum Concentration of Vitamin D and Breast Cancer Characteristics: A Prospective Observational Mediterranean Study. Clinical Breast Cancer. 17(7). 559–563.
18.
Bonotto, Marta, Lorenzo Gerratana, Massimo Di Maïo, et al.. (2016). Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis. The Breast. 31. 114–120.
19.
Montemurro, Filippo, Serena Di Cosimo, & Grazia Arpino. (2013). Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications. Annals of Oncology. 24(11). 2715–2724.
20.
Laurentiis, Michelino De, Daniela Cianniello, R. Caputo, et al.. (2010). Treatment of triple negative breast cancer (TNBC): current options and future perspectives. Cancer Treatment Reviews. 36. S80–S86.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Rinat Yerushalmi Breakdown of academic impact, for papers by Jacques Bonneterre Breakdown of academic impact, for papers by Robert Mennel Breakdown of academic impact, for papers by Nicholas J. Robert Breakdown of academic impact, for papers by Henri Roché Breakdown of academic impact, for papers by Lynn G. Dressler Breakdown of academic impact, for papers by Binghe Xu Breakdown of academic impact, for papers by Rita Nanda Breakdown of academic impact, for papers by Pär‐Ola Bendahl Breakdown of academic impact, for papers by Antonio Llombart‐Cussac